Key insights
- Stryker's stock hit a 52-week low amid a challenging year. An acquisition and a cyberattack have impacted operations. Truist Securities reiterated a Hold rating. The stock's decline and mixed news create slight negative pressure on the broader medical device sector.
Stryker Corporation stock has reached a new 52-week low, hitting 317.67 USD, trading just above its 52-week low of 319.32 USD and down 21% from its 52-week high of 404.87 USD. This development comes amid a challenging year for the medical device giant with a market cap of 123.1 billion USD, which has seen its stock value decline by 14.04% over the past 12 months. The medical technology firm, known for its innovative healthcare solutions, has faced market pressures that have contributed to this downturn. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of 345.42 USD suggesting potential upside. As investors assess the broader economic landscape and its impact on the healthcare sector, Stryker Corporation’s recent stock performance underscores the volatility that companies in this industry are currently navigating. For deeper insights into Stryker’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities on InvestingPro.
In other recent news, Stryker has announced the acquisition of Amplitude Vascular Systems, a company specializing in intravascular lithotripsy technology for treating calcified peripheral arterial disease. This acquisition is expected to enhance Stryker’s Peripheral Vascular portfolio once the product receives clearance for use in applicable markets. Additionally, Stryker has faced a cyberattack linked to Iran, which has materially impacted their first-quarter operations. Following this update, Truist Securities reiterated a Hold rating on Stryker stock with a price target of $395.00.
In another development, Stryker has appointed Nick Mead as Vice President of Investor Relations, effective May 1, 2026. Mead has been with Stryker for nearly 20 years, most recently serving as Vice President of Finance for the Medical division. His experience spans leadership roles across various divisions and business units within the company. These recent developments highlight Stryker’s strategic movements and challenges in the current business landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.